CRVS
Corvus Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.32B
P/E Ratio
—
EPS
$-0.53
Beta
0.97
52W High
$26.95
52W Low
$2.98
50-Day MA
$17.43
200-Day MA
$9.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-42.87M |
| Operating Margin | 0.00% |
| Return on Equity | -32.60% |
| Return on Assets | -38.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.82 |
| Price-to-Book | 20.16 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $83.99M |
| Float | $72.22M |
| % Insiders | 3.51% |
| % Institutions | 57.16% |
Analyst Ratings
Consensus ($35.17 target)
1
Strong Buy6
BuyData last updated: 4/10/2026